mRNA vaccines manufacturing: Challenges and bottlenecks

Area of Science:

• Biotechnology
• Vaccinology
• Public Health

Background:

• Messenger RNA (mRNA) vaccines are emerging as a powerful tool in public health and infectious disease control.
• Their precision, safety, and manufacturing flexibility make them a promising alternative to conventional vaccines.
• mRNA vaccine technology was pivotal in combating the COVID-19 pandemic and is being explored for various diseases, including cancer and genetic disorders.

Purpose of the Study:

• To review the current state-of-the-art in mRNA vaccine technology.
• To identify challenges and bottlenecks in the manufacturing of mRNA vaccines.
• To discuss the requirements for cost-effective and large-scale production of mRNA vaccines.

Main Methods:

• In vitro synthesis of mRNA.
• Purification strategies including DNase digestion, precipitation, chromatography, and tangential flow filtration.
• Review of current manufacturing platforms and processes.

Main Results:

• mRNA vaccines have demonstrated significant success, particularly during the COVID-19 pandemic.
• The technology is being investigated for a wide range of therapeutic applications beyond infectious diseases.
• Current large-scale production involves multi-step in vitro reactions and purification processes.

Conclusions:

• mRNA vaccines represent a significant advancement in vaccination technology.
• Addressing manufacturing challenges is crucial for enabling rapid and cost-effective responses to health emergencies.
• Further optimization of production processes is needed to fully realize the potential of mRNA vaccines.